Complement in the Homeostatic and Ischemic Brain by Ali Alawieh et al.
August 2015 | Volume 6 | Article 4171
Review
published: 12 August 2015
doi: 10.3389/fimmu.2015.00417
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Hans-Peter Hartung, 
Heinrich-Heine University 
Düsseldorf, Germany
Reviewed by: 
Tanja Kuhlmann, 
Universitätsklinikum Münster, 
Germany 
Rowan Paul Orme, 
Cardiff University, UK
*Correspondence:
 Stephen Tomlinson, 
Department of Microbiology and 
Immunology, Medical University of 
South Carolina, 173 Ashley Avenue, 
BSB 203, MSC 504, Charleston, 
SC 29425, USA 
tomlinss@musc.edu
Specialty section: 
This article was submitted to Multiple 
Sclerosis and Neuroimmunology, a 
section of the 
journal Frontiers in Immunology
Received: 26 March 2015
Accepted: 30 July 2015
Published: 12 August 2015
Citation: 
Alawieh A, Elvington A and 
Tomlinson S (2015) Complement in 
the homeostatic and ischemic brain. 
Front. Immunol. 6:417. 
doi: 10.3389/fimmu.2015.00417
Complement in the homeostatic and 
ischemic brain
Ali Alawieh 1, Andrew Elvington 2 and Stephen Tomlinson 3*
1 Neuroscience Institute, Department of Neurosciences, Medical University of South Carolina, Charleston, SC, USA, 
2 Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA, 3 Department of 
Microbiology and Immunology, Ralph H. Johnson Veteran Affairs Medical Center, Medical University of South Carolina, 
Charleston, SC, USA
The complement system is a component of the immune system involved in both rec-
ognition and response to pathogens, and it is implicated in an increasing number of 
homeostatic and disease processes. It is well documented that reperfusion of ischemic 
tissue results in complement activation and an inflammatory response that causes 
post-reperfusion injury. This occurs following cerebral ischemia and reperfusion and trig-
gers secondary damage that extends beyond the initial infarcted area, an outcome that 
has rationalized the use of complement inhibitors as candidate therapeutics after stroke. 
In the central nervous system, however, recent studies have revealed that complement 
also has essential roles in synaptic pruning, neurogenesis, and neuronal migration. In the 
context of recovery after stroke, these apparent divergent functions of complement may 
account for findings that the protective effect of complement inhibition in the acute phase 
after stroke is not always maintained in the subacute and chronic phases. The devel-
opment of effective stroke therapies based on modulation of the complement system 
will require a detailed understanding of complement-dependent processes in both early 
neurodegenerative events and delayed neuro-reparatory processes. Here, we review 
the role of complement in normal brain physiology, the events initiating complement 
activation after cerebral ischemia-reperfusion injury, and the contribution of complement 
to both injury and recovery. We also discuss how the design of future experiments may 
better characterize the dual role of complement in recovery after ischemic stroke.
Keywords: complement, stroke, innate immunity, neuroprotection, brain ischemia, reperfusion injury
introduction
Following cerebral ischemia, most patients reperfuse at least part of the ischemic area (1), and the 
restoration of blood flow initiates an inflammatory cascade that causes secondary neuronal injury 
which can have a significant impact on functional recovery. Reperfusion can occur spontaneously, 
or can be achieved by surgical or pharmacological means (2). Once reperfusion occurs, there is 
an inflammatory reaction in which resident cells, neutrophils, macrophages, platelets, cytokines, 
molecular oxygen, and complement play important roles, and which culminates in necrotic and 
apoptotic cell death (3). The only approved pharmacological agent for the treatment of ischemic 
stroke is recombinant tissue-type plasminogen activator (tPA), which promotes reperfusion by 
enhancing the dissolution of blood clots. However, tPA must be administered with 3 h of symptom 
onset, and since there is a risk of uncontrollable intracranial hemorrhage, physicians are often reluc-
tant to use this drug, with the result that only about 5% of stroke patients are treated with tPA (4, 5). 
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C5b. C5b initiates the terminal pathway and formation of the 
membrane attack complex (MAC) that can cause direct cell lysis, 
but that can also stimulate cells to release inflammatory molecules. 
The anaphylatoxins C3a and C5a have multiple physiologic and 
inflammatory activities, including the recruitment and activation 
leukocytes. Complement is regulated by various fluid-phase and 
membrane-bound inhibitors [reviewed in Ref. (12)].
Complement in Brain Homeostasis
In contrast to systemic complement proteins that are produced 
predominantly by the liver, complement proteins are also be syn-
thesized locally in the CNS. Primary studies using astrocyte and 
glial cell cultures demonstrated that these cells express nearly all 
components of the complement system (6–8). It was also shown 
that bacterial infection or inflammation increased expression of 
complement mRNA in the CNS (13, 14). Early studies focused on 
the protective role that the complement system played in the CNS, 
including sensing and response to infection, and the clearance 
of debris, apoptotic cells, and plaques (15–18). Further Research 
has also uncovered an essential role for complement in key 
aspects of brain function such as in synaptic pruning during CNS 
development, as well as other forms of synaptic plasticity (19–21). 
Evidence for the role of complement in elimination of synapses 
came from studies on the development of the retinogeniculate 
pathway in mice (19–21). C1q and C3 proteins produced by astro-
cytes were found to tag weaker synapses for removal by microglia, 
which drives specific innervation. This process reduces excessive 
connectivity between brain areas that may seed epileptogenesis as 
reported in C1q−/− mice (22). In addition, the anaphylatoxins, C3a 
and C5a, have also been implicated in cerebellar development in 
neonatal rats. C3a and C5a receptors (C3aR and C5aR1) were 
transiently elevated in rat cerebellar granule neurons peaking 
on the 12th postnatal day (23), and agonists to these receptors 
transiently altered the thickness of cerebellar cortical levels. A 
C5a agonist caused enlargement of the external granule layer and 
promoted granule cell survival by inhibiting caspase-9 activity and 
maintaining mitochondrial integrity. A C3a agonist increased the 
thickness of the internal granule layer while reducing the thick-
ness of the external granule layer, suggesting a putative role of C3a 
in accelerating the migration of granule cells from the external to 
internal granule layer (23, 24).
Components of classical and terminal complement pathways, 
along with the complement anaphylatoxins, have also been shown 
to play a role in neurogenesis and neuroprotection. The addition 
of C1q to rat primary neuronal cultures resulted in alteration 
in microRNA and mRNA expression in a direction promoting 
neuronal survival (25). Pathways implicated in this effect include 
cholesterol metabolism, synaptic function, and neuronal growth 
factor production. A similar neuroprotective role for C1q was 
reported in response to β-amyloid and serum amyloid P-induced 
neurotoxicity (26). Interestingly, the MAC also demonstrated a 
pro-survival effect on oligodendrocyte progenitor cells at sublytic 
concentrations. Different pathways were thought to mediate the 
survival and proliferative effects of sublytic MAC on oligodendro-
cyte progenitor cells in vitro, including the inhibition of caspase-3 
and caspase-8 activation, upregulation of bcl-2 expression, 
FiGURe 1 | Basic outline of the principle pathways of complement 
activation and complement effector molecules. The classical pathway is 
triggered by the binding of C1q to antibody Fc regions, pentraxins or certain 
cell surface determinants. The lectin pathway is triggered by Mannose-
binding lectin (MBL) or ficolins which bind to carbohydrate patterns, including 
those found on some IgM antibodies. Both pathways lead to cleavage of C2 
and C4 components, forming the classical pathway C3 convertase (C4b2a) 
that cleaves C3. The alternative pathway is spontaneously activated forming 
the alternative pathway C3 convertase (C3bBb), and it also serves to amplify 
classical and lectin pathway activation. Cleavage of C3 leads to the 
generation of C3a and C3b. Activated C3b deposits on cell surfaces and is 
further degraded to iC3b, C3dg, and C3d, which serve as opsonins for 
receptors on immune cells. In addition, C3b associates with preformed C3 
convertase, forming C5 convertase that in turn cleaves C5 into C5a and C5b. 
Deposition of C5b on cell surface initiates assembly of the cytolytic 
membrane attack complex (MAC or C5b-9). The C5a and C3a 
anaphylatoxins are potent pro-inflammatory molecules, and also modulate 
various homeostatic effects through G-protein signaling.
There is thus a significant need for new and effective approaches 
to treat stroke, and reducing inflammation and secondary injury 
in the area surrounding the ischemic core (i.e., the penumbra) is a 
major therapeutic goal. Nevertheless, it is becoming increasingly 
clear that inflammation also has homeostatic functions within 
the brain, and post-ischemic inflammation is also associated with 
neural protection and regeneration. Therefore, understanding 
how inflammation is involved in the balance between neurode-
generative and neuroprotective mechanisms will be important 
for the development of therapeutics that optimally promote long-
term functional recovery after stroke. Here, we review the role 
of complement in neuroinflammatory processes during brain 
homeostasis and in the post-ischemic brain.
In the CNS, as in other organs and tissues, complement plays a 
key role in the inflammatory reaction following ischemia and rep-
erfusion. Disruption of the blood–brain barrier following ischemic 
stroke allows access of complement proteins to the brain, although 
proteins of the complement system can be locally produced by 
the cells of the CNS (6–8). Complement is implicated in human 
ischemic stroke by studies demonstrating complement activation 
in patients. Complement activation and deposition in areas of 
cerebral ischemia has also been shown in rodent models of focal 
cerebral ischemia, together with the upregulation of various com-
plement proteins within the CNS. Studies utilizing complement 
inhibited mice or mice genetically deficient in various complement 
proteins have further helped elucidate the role of complement 
in the pathogenesis of ischemic stroke and functional recovery. 
However, as with other inflammatory processes, more recent stud-
ies have also documented a role for complement in homeostatic 
functions within the brain, and complement is also associated with 
post-ischemic neural protection, repair, and regeneration.
The Complement System
In addition to its well-documented role in host defense, comple-
ment plays important roles in various other physiologic and 
homeostatic functions, such as immune complex catabolism, the 
clearance of dead and dying cells, and the modulation of adap-
tive immune responses. Complement is also involved in various 
developmental and regenerative processes, and is integrated with 
multiple other biological systems and pathways [reviewed in Ref. 
(9)]. Complement activation products consisting of opsonins, 
anaphylatoxins, and a terminal cytolytic complex mediate the 
effector functions of complement. The complement cascade is 
activated by one of three pathways, referred to as the classical, 
alternative, and lectin pathways, and all pathways converge at the 
cleavage and activation of the complement protein C3 (Figure 1). 
In general, the classical pathway is activated by antibodies and 
apoptotic cells via recognition by C1q, and the lectin pathway is 
activated via recognition of carbohydrate patterns by mannose-
binding lectin (MBL) or ficolins. The alternative pathway is con-
stitutively active, and spontaneously hydrolyzed C3 can become 
deposited on any surface to take part in further C3 activation on 
that surface. An alternative pathway-activating surface is one that 
is unable to regulate further C3 activation and amplification. The 
alternative pathway also functions to amplify the classical and 
lectin pathways. There are, however, additional means by which 
complement can be activated. Extrinsic protease pathways can 
bypass the early pathways of complement activation and directly 
cleave C3 or C5 proteins; for example, thrombin can directly 
cleave C3 and act as a C5 convertase (10, 11). The initial products 
of C3 cleavage are soluble C3a and cell-bound C3b. C3b is further 
cleaved to yield membrane-bound iC3b, C3dg, and C3d opsonins 
that are recognized by receptors on immune cells. C3 cleavage also 
leads to C5 cleavage to yield soluble C5a and membrane-bound 
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C5b. C5b initiates the terminal pathway and formation of the 
membrane attack complex (MAC) that can cause direct cell lysis, 
but that can also stimulate cells to release inflammatory molecules. 
The anaphylatoxins C3a and C5a have multiple physiologic and 
inflammatory activities, including the recruitment and activation 
leukocytes. Complement is regulated by various fluid-phase and 
membrane-bound inhibitors [reviewed in Ref. (12)].
Complement in Brain Homeostasis
In contrast to systemic complement proteins that are produced 
predominantly by the liver, complement proteins are also be syn-
thesized locally in the CNS. Primary studies using astrocyte and 
glial cell cultures demonstrated that these cells express nearly all 
components of the complement system (6–8). It was also shown 
that bacterial infection or inflammation increased expression of 
complement mRNA in the CNS (13, 14). Early studies focused on 
the protective role that the complement system played in the CNS, 
including sensing and response to infection, and the clearance 
of debris, apoptotic cells, and plaques (15–18). Further Research 
has also uncovered an essential role for complement in key 
aspects of brain function such as in synaptic pruning during CNS 
development, as well as other forms of synaptic plasticity (19–21). 
Evidence for the role of complement in elimination of synapses 
came from studies on the development of the retinogeniculate 
pathway in mice (19–21). C1q and C3 proteins produced by astro-
cytes were found to tag weaker synapses for removal by microglia, 
which drives specific innervation. This process reduces excessive 
connectivity between brain areas that may seed epileptogenesis as 
reported in C1q−/− mice (22). In addition, the anaphylatoxins, C3a 
and C5a, have also been implicated in cerebellar development in 
neonatal rats. C3a and C5a receptors (C3aR and C5aR1) were 
transiently elevated in rat cerebellar granule neurons peaking 
on the 12th postnatal day (23), and agonists to these receptors 
transiently altered the thickness of cerebellar cortical levels. A 
C5a agonist caused enlargement of the external granule layer and 
promoted granule cell survival by inhibiting caspase-9 activity and 
maintaining mitochondrial integrity. A C3a agonist increased the 
thickness of the internal granule layer while reducing the thick-
ness of the external granule layer, suggesting a putative role of C3a 
in accelerating the migration of granule cells from the external to 
internal granule layer (23, 24).
Components of classical and terminal complement pathways, 
along with the complement anaphylatoxins, have also been shown 
to play a role in neurogenesis and neuroprotection. The addition 
of C1q to rat primary neuronal cultures resulted in alteration 
in microRNA and mRNA expression in a direction promoting 
neuronal survival (25). Pathways implicated in this effect include 
cholesterol metabolism, synaptic function, and neuronal growth 
factor production. A similar neuroprotective role for C1q was 
reported in response to β-amyloid and serum amyloid P-induced 
neurotoxicity (26). Interestingly, the MAC also demonstrated a 
pro-survival effect on oligodendrocyte progenitor cells at sublytic 
concentrations. Different pathways were thought to mediate the 
survival and proliferative effects of sublytic MAC on oligodendro-
cyte progenitor cells in vitro, including the inhibition of caspase-3 
and caspase-8 activation, upregulation of bcl-2 expression, 
FiGURe 1 | Basic outline of the principle pathways of complement 
activation and complement effector molecules. The classical pathway is 
triggered by the binding of C1q to antibody Fc regions, pentraxins or certain 
cell surface determinants. The lectin pathway is triggered by Mannose-
binding lectin (MBL) or ficolins which bind to carbohydrate patterns, including 
those found on some IgM antibodies. Both pathways lead to cleavage of C2 
and C4 components, forming the classical pathway C3 convertase (C4b2a) 
that cleaves C3. The alternative pathway is spontaneously activated forming 
the alternative pathway C3 convertase (C3bBb), and it also serves to amplify 
classical and lectin pathway activation. Cleavage of C3 leads to the 
generation of C3a and C3b. Activated C3b deposits on cell surfaces and is 
further degraded to iC3b, C3dg, and C3d, which serve as opsonins for 
receptors on immune cells. In addition, C3b associates with preformed C3 
convertase, forming C5 convertase that in turn cleaves C5 into C5a and C5b. 
Deposition of C5b on cell surface initiates assembly of the cytolytic 
membrane attack complex (MAC or C5b-9). The C5a and C3a 
anaphylatoxins are potent pro-inflammatory molecules, and also modulate 
various homeostatic effects through G-protein signaling.
cleavage of Bid, increase in cellular FLIP long isoform, and down-
regulation of FasL expression (27, 28). The use of PI3K inhibitor 
(LY294002) partly reversed the effects of MAC on oligodendro-
cyte survival, suggesting that sublytic MAC concentrations may 
promote downstream signaling through the PI3K pathway (28). 
On the other hand, it has been shown that complement receptor 
2 (CR2) is expressed in adult neural progenitor cells of the dentate 
gyrus, and that the CR2 ligands C3d and interferon-α inhibit 
neural progenitor cell proliferation. Furthermore, CR2-deficient 
mice displayed increased basal neurogenesis, indicating that CR2 
may regulate neurogenesis and that complement activation (via 
C3d generation) may inhibit neurogenesis (29).
The C3a and C5a anaphylatoxins signal through the C3aR and 
C5aR1 G-protein coupled receptors, but we lack a clear under-
standing of their function and downstream effector mechanisms 
in the CNS. Certainly both anaphylatoxins can promote the 
production of cytokines and inflammatory mediators, and can 
direct and activate leukocytes, but they can also affect neuronal 
survival and synaptic plasticity. For example, C5aR1 is expressed 
on pre-synaptic terminals of mossy fibers within the hippocam-
pus, suggesting a possible role for this receptor in synaptic/
cellular plasticity (30). In addition, expression of C3aR on both 
neurons and glial cells suggests that C3a may play a role beyond 
immunological protection (31). Several studies have investigated 
common and different neuroprotective mechanisms of C3a and 
C5a. C3a was found to be involved in basal and ischemia-induced 
neurogenesis that was inhibited in C3-deficient mice and in mice 
treated with C3a receptor antagonist (C3aRA) (32). In murine 
primary neuronal cultures, C3a reversibly bound to neuronal cells 
promoting migration and differentiation through the recruitment 
of the intracellular ERK1/2 signaling pathway (33). C5a also 
recruited the ERK1/2 signaling pathway in response to glutamate-
induced neurotoxicity (34). In this latter study, C5a was found 
to inhibit DNA fragmentation and pro-caspase-3 activation in 
neuronal and hippocampal cultures. Both C3a and C5a were 
found to increase the gene expression of neuronal growth factor 
in microglia, an effect mediated by C3aR and C5aR1 and inhibited 
by pertussis toxin (that blocks G-protein (Gi) coupled receptors) 
(35, 36). The increase in neuronal growth factor mRNA levels was 
not always associated with significant protein upregulation, but a 
significant synergistic effect of both anaphylatoxins with IL-1β on 
neuronal growth factor protein upregulation has been reported 
(36). Both C3a and C5a contributed to neuroprotection from 
glutamate-induced excitotoxicity, although each peptide had a dif-
ferent specific protective pattern. C3a was only protective against 
N-methyl-d-aspartate (NMDA) in the presence of astrocytes, and 
did not contribute to neuroprotection against Kainaite-induced 
excitotoxicity (37). By contrast, C5a exhibited a neuroprotec-
tive role in Kainaite rather than NMDA neurotoxicity. Also, 
intraventricular infusion of both Kainic acid and C5a in mice 
reduced caspase-3 activation and neuronal apoptosis (38), and 
C5aR1-deficient mice were shown to have increased susceptibility 
to Kainaite-induced excitotoxicity compared to wild type; treat-
ment of wild-type mice with C5a reversed the glutamate-induced 
decrease in GluR2 receptor and reduced neuronal apoptosis (39). 
More recently, C5a was shown to reduce extracellular glutamate 
accumulation through the upregulation of glutamate transporter 
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GLT-1 in microglia, suggesting a distinct mechanism of protec-
tion against excitotoxicity (40). Figure 2 summarizes the interplay 
between the complement system and other immune components 
in brain physiology and response to pathology.
Complement in Brain ischemia and 
Reperfusion injury
The complement system has long been recognized as a potential 
therapeutic target for the reduction of secondary damage and 
improvement of outcome after stroke. Research has focused on 
identifying the role of complement in brain ischemia-reperfusion 
injury (IRI) and investigating how complement inhibition affects 
outcome in models of stroke. There follows a summary of studies 
that have been performed in vitro, in animal models of ischemic 
and hemorrhagic stroke, and in human stroke.
insight from In Vitro Studies
Oxygen-glucose deprivation of cultured neuronal cells is a widely 
used in vitro model for cerebral ischemia, a procedure that results 
in both apoptotic and necrotic cell death. Upon hypoxic insult, 
neuronal cultures have been shown to overexpress several comple-
ment proteins. Both mRNA and protein levels of C1q were elevated 
in rat neuronal cells exposed to hypoxia, and newly produced C1q 
preferentially deposited on hypoxic neurons, serving as both a 
primary opsonin and an activator of the complement cascade (41). 
Similarly, mouse and rat neuronal cell cultures showed increased 
C3 expression in response to hypoxia, a response that was shown 
to be associated with activation of caspase-3, a marker for apop-
tosis. Both C3 expression and caspase-3 activation were reduced 
with intravenous immunoglobulin (IVIG) treatment, suggesting 
that IVIG may represent an interventional therapy for stroke 
FiGURe 2 | The interplay between complement system and other immune components in normal and pathological brain.
(42, 43). In addition, blocking C5a signaling by the use of C5aR1 
antagonist or the use of neurons from C5aR1-deficient mice 
reduced ischemia-induced apoptosis in murine neuronal cultures 
indicating a pathogenic role for C5a (44, 45). The neuroprotective 
effect of C5aR1 antagonism could be enhanced with hypothermia 
without alteration in C5aR1 levels, suggesting a putative therapeu-
tic advantage of coupling both treatments (45). On the other hand, 
human neurons were found to express the complement inhibitors 
CD59, CD46 (membrane cofactor protein) and CD55 (decay 
accelerating factor), and hypoxic insult neither altered inhibitor 
expression nor the deposition of C3d, suggesting that human 
neurons are protected from the effects of C3 opsonization and the 
MAC (46). Table 1 shows a brief summary of the different in vitro 
studies on complement involvement in experimental stroke.
In Vivo Studies
Animal models of ischemic stroke involve transient or permanent 
occlusion of the middle cerebral artery or common carotid artery, 
or cerebral clot embolization. Notably, the advantage of the cer-
ebral embolization model, although more difficult and less com-
monly utilized, is that it better allows the evaluation of the effect 
of potential adjuvant therapies to tissue plasminogen activator 
(t-PA), the only approved treatment for acute stroke. As a plasma 
protease, t-PA is capable of proteolytically activating components 
of the complement system via the recently recognized extrinsic 
pathway. In support of this, an early study reported that after 
cerebral embolization rabbits treated with t-PA had higher levels 
of C3 and C5 compared to vehicle (47). Interestingly, complement 
depletion in the same model using cobra venom factor (CVF) did 
not have any effect on infarct size in the presence or absence of t-PA 
treatment (48). However, this study did not investigate other out-
come measures that complete complement depletion may affect, 
TABLe 1 | Summary of in vitro studies on the role of complement in cerebral i/R.
Study Disease Cell type Model Treatment Pathway Findings
(43) Ischemic 
stroke
Mouse cortical 
neuron culture
Oxygen-glucose 
deprivation (3 h)
siRNA C3 
inhibition
All pathways (1) Inhibition of C3 expression reduced oxidative stress. (2) Ischemia 
promotes an increase in C3 promoter activity
(44) Ischemic 
stroke
Mouse cortical 
neuron culture
Oxygen-glucose 
deprivation (12 h)
C5a C5aRA 
(PMX53)
All pathways (1) C5a caused neuronal apoptosis through C5aR. (2) PMX53 blocked 
ischemia-induced apoptosis
 (41) Ischemic 
stroke
Rat PC 12 cells Hypoxic chamber 
(9 h)
None Classical 
pathway
(1) C1q mRNA was not expressed in PC12 but started to be expressed 
after hypoxia. (2) C1q protein antibody bound to the cells after hypoxia
 (42) Ischemic 
stroke
Rat embryo 
neuronal culture
Oxygen-glucose 
deprivation (24 h)
IVIG All pathways (1) C3 levels increased in cultured neurons upon OGD with a parallel 
increase in caspase-3. (2) IVIG reduced the levels of C3 and caspase-3 
after OGD
(45) Ischemic 
stroke
Astrocyte mouse 
culture
Oxygen-glucose 
deprivation 
(6–12 h)
C5aRA 
C5aR−/−
All pathways (1) C5aRA after OGD and C5aR−/− significantly reduced cell death and 
cytoplasmic LDH release. (2) Neuroprotective effect of C5aRA was 
enhanced upon hypothermia. (3) Expression of C5aR was not affected by 
hypothermia
(46) Ischemic 
stroke
NT2-N human 
neuronal culture
1 and 0.1% 
hypoxia for 3 h
None All pathways (1) CD59 was strongly expressed on NT2-N neurons along with CD55, 
CD46, C3aR, and C5aR. (2) Only CD55 was affected by hypoxia with a 
reduction of expression. (3) Hypoxia exposure did not affect deposition 
of C3d
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and no subsequent studies have further investigated the crosstalk 
between t-PA and the complement system in the context of acute 
stroke treatment (Table 2). The use of CVF in rodent models of 
transient ischemia consistently demonstrates a protective effect 
of complement depletion. Rats subjected to bilateral transient 
common carotid artery occlusion and pretreated with CVF had 
a better outcome compared to control treated rats in terms of 
somatosensory evoked potentials (49). CVF also reduced infarct 
volume and neuronal atrophy after rat transient middle cerebral 
artery occlusion (MCAO), as well as after neonatal rat hypoxia 
(50, 51). However, in permanent ischemia rat model, CVF did 
not effectively reduce infract volume (52). The prominent role of 
reperfusion in the activation of plasma complement proteins near 
ischemic tissue may explain why complement depletion did not 
alter outcomes in models utilizing permanent ischemia.
Following stroke, damage to the blood–brain barrier will 
allow access of hematogenous complement proteins to the CNS, 
but there is evidence that increased local expression of comple-
ment proteins contribute to secondary injury after ischemia. For 
example, expression of C1q, C3, and CD11b (a component of 
complement receptor 3 expressed on phagocytes) is upregulated 
in response to ischemia in models of transient MCAO (54, 58, 
60, 81). Interestingly, the increase in C1q mRNA expression was 
specific to microglia and did not occur in neurons or astrocytes 
(54), but C1q protein in the ischemic brain co-localized with 
the neuronal marker MAP2, suggesting that C1q is produced by 
microglia in response to ischemia and accumulates on neuronal 
cells (58). However, despite increased expression of C1q, the role 
of the classical pathway in post-ischemic injury is not completely 
clear since whereas C1q deficiency protects against murine neo-
natal hypoxic-ischemic brain injury (79, 85), it does not protect 
against murine transient MCAO (60). In neurodegenerative dis-
eases, C1q and or C3 opsonization of synapses stimulates micro-
glial phagocytosis, and complement-mediated synaptic clearance 
precedes neuronal loss (21, 86). During development, however, 
C1q and C3 opsonins have been shown to play an essential role 
in synaptic pruning and neuron remodeling (21). A feature of 
cerebral IRI is that it carries characteristics of both neurodegen-
erative disease and developmental mechanisms. Activation of 
inflammatory cascades after stroke causes significant secondary 
injury resulting in loss of both synapses and neurons in the 
penumbra area. Following this early insult, stroke is characterized 
by a window of neuroplastic response that mimics early develop-
mental mechanisms including axonal growth and sprouting, and 
formation of new synapses and intra-cortical projections (87–89) 
[see reviews (90, 91)]. An important, yet unexplored question, 
is whether inhibition of the complement system after cerebral 
ischemia and reperfusion reduces loss of synaptic connections 
in the ischemic penumbra or whether this inhibition will prevent 
adequate synaptic pruning during rehabilitation induced cortical 
re-organization.
In an influential paper on the application of complement inhibi-
tion in stroke, Huang et al. described the use of soluble complement 
receptor 1 (sCR1) and its sialyl Lewis × glycosylated form (sCR1-
sLex) to study the effect of systemic complement inhibition and 
selectin-targeted complement inhibition on outcomes after murine 
stroke. Soluble CR1 inhibits all complement pathways at the C3 
activation step, and the sLex carbohydrate moiety binds to both P 
and E selectin, adhesion molecules that are upregulated on activated 
endothelium. Following MCAO and reperfusion, sCR1 modestly 
reduced ischemic injury while sCR1-sLex markedly diminished 
infarct volume, improved neurological outcome, and inhibited 
leukocyte migration (55). Thus, decoration sCR1 with the sLex 
moiety increased the efficacy of complement inhibition by target-
ing the inhibitor to selectin-expressing activated brain endothelial 
surfaces. A more recent study demonstrated that a truncated form 
of sCR1 also significantly improved outcome in a rat model of tran-
sient MCAO (78). Nevertheless, studies in a non-human primate 
stroke model failed to reproduce the earlier findings of sCR1 and 
sCR1-sLex treatment that was reported in mice (59). Similarly, the 
therapeutic value of sCR1-sLex failed to translate to baboons in a 
study by Ducruet et al. (66). In this latter study, sCR1-sLex reduced 
TABLe 2 | Summary of studies investigating the role of complement in cerebral i/R using animal models.
Study Disease Species Model Treatment Pathway Findings
(53) Hemorrhagic 
stroke
Mouse Intracerebral hemorrhage C3−/−
C5−/−
WT + C5aRA (PMX53)
WT
All pathways (1) C3−/− had less brain edema but more cognitive and neurological deficit compared to C5−/−. (2) 
C5aR peaks at day 3 and is not expressed in sham. (3) C5aRA decreases C5aR expression and 
improves functional outcome alone and in combination with anti-thrombin therapy up to 5 days 
after surgery
(43) Ischemic stroke Mouse Transient-MCAO (45 min 
occlusion time)
SOD1Tga All pathways (1) SOD2KO had higher oxidative stress and increased brain C3 expression. (2) C3 expression 
involved microglia and neurons. (3) C3 expression was reduced by PBN compared to vehicle, and 
was reduced in SOD1Tg compared to WT up to 7 days after ischemia. (4) PBN reduced infarct 
volume and improved outcome up to 7 days after ischemia
SOD2−/−
WT
WT + PBNb
(44) Ischemic stroke Mouse Transient- MCAO (1 h 
occlusion time)
CD88−/− (C5aR) All pathways (1) C5aR−/− were protected against ischemia compared to WT. (2) C5a increase post-ischemia in 
WT specifically in neurons. (3) C5−/− had a reduced lesion volume and better neurological outcome 
compared to WT 24 h after reperfusionC5
−/−
WT + C5a
(47) Ischemic stroke Rabbit Cerebral embolization WT + t-PA All pathways Both C5 and C3 were significantly more activated in t-PA-treated rabbits compared to vehicle
(48) Ischemic stroke Rabbit Cerebral embolization WT + CVFc +/− t-PA All pathways Complement depletion did not have effect on infarct size up to 7 h after embolization in any of the 
groups compared to controls
(54) Ischemic stroke Rat Transient global cerebral 
ischemia (15 min)
None Classical 
pathway
(1) Ischemia increased C1q mRNA expression and activity 24–72 h. (2) C1q was specifically 
expressed in microglia not in neurons or astrocytes
(55) Ischemic stroke Mouse Transient- MCAO (45 min 
occlusion time)
WT + sCR1 (block C1q) All pathways (1) sCR1 modestly reduced acute (24 h) injury given just before ischemia. (2) sCR1-sLex markedly 
diminished infarct volume in a dose-dependent fashion and improved neurological outcome more 
than sCR1. (3) Ischemia had threefold increase in leukocyte migration that was inhibited by sCR1-
Lex and not sCR1. Measurements were performed 24 h after ischemia
WT + sCR1-sLex (block C1q 
and selectin)
(56) Ischemic stroke Rat Transient- MCAO (60 min 
occlusion time)
WT + C1 inhibitor Classical 
pathway
Given reperfusion, C1 inhibitor reduced the infarct volume as well as myeloperoxidase activity 48 h 
after reperfusion.
(57) Ischemic stroke Mouse Transient- MCAO (60 min 
occlusion time)
WT + CR2-Crry 
(30 min-postR)
All pathways (1) C3−/− and CR2-Crry-treated mice had improved survival, reduced infarct volume and expression 
of P-selectin and improvement of neurological outcome at 24 h after reperfusion. (2) C3−/− had less 
apoptotic neurons than sham and CR2-Crry 
CD3−/−
(58) Ischemic stroke Mouse Transient- MCAO (60 min 
occlusion time)
None Classical 
pathway
(1) C1q begins to accumulate in the brain after 6 h of ischemia. (2) C1q colocalizes with MAP2 on 
neurons during ischemia
(59) Ischemic stroke Baboons Transient- MCAO (75 min 
occlusion time)
WT + sCR1 All pathways (1) C1q blockade by sCR1 did not affect infarct volume or neurological outcome up to days after 
surgery. (2) C1q was deposited in the ischemic brain of vehicle-treated baboons and sCR1 was 
detected in the other group at 72 h after ischemia
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(60) Ischemic stroke Mouse Transient- MCAO (60 min 
occlusion time)
C1qa−/−
C3−/−
C5−/−
WT + C3aRA
Classical and 
common 
terminal 
pathway
(1) C1q, C3, and C5 deposited in the ischemic side of WT but not contralaterally. (2) C1q−/− did 
not experience improvement in cerebral infarct volumes, neurological outcome, or mortality 
compared to WT. (3) C3−/− and C3aRA-treated WT had significant improvement in infarct volume 
and neurological outcome with less granulocyte infiltration and no effect on mortality. (4) C3−/− 
improvement was reversed in C3-treated C3−/− mice. (5) C5−/− did not have significant change in 
infarct volume or mortality. Outcomes were assessed 24 h after ischemia
(49) Ischemic stroke Rat Bilateral common carotid 
artery occlusion (15 min)
WT + CVFc pretreatment Non-specific CVF improved neurological outcome as measured by somatosensory evoked potentials up to 4 h 
after reperfusion
(61) Neonatal 
hypoxic-
ischemic 
encephalitis
Rat Unilateral common carotid 
ligation and hypoxic 
atmosphere exposure
C9−/− + sCR1
C9−/− + sCR1-sLex
C9−/− + CVFc
C9−/− + C9
Classical and 
common 
terminal 
pathway
(1) sCR1, sCR1-sLex, or CVF did not affect the infarct volume in C9−/− neonatal rats. (2) C9 
administration caused a significant increase in infarct volume in C9−/− compared to vehicle 
measured after 24 h
(50) Neonatal 
hypoxic-
ischemic 
encephalitis
Rat Unilateral common carotid 
ligation and hypoxic 
atmosphere exposure
WT + CVFc All pathways (1) Hypoxia-induced iC3b and C9 accumulation in the brain after 16 and 24 h, respectively. (2) 
C3 and C9 first localized to endothelium and then to neurons. (3) CVF given 24 h before ischemia 
reduced infarct size without eliminating complement deposition mainly C9
(62) Ischemic stroke Mouse Transient- MCAO 120 min 
occlusion time
WT + C1 Inhibitor Classical 
pathway
(1) C1 inhibitor given after ischemia reduced focal and general deficit as well as ischemic volume at 
48 h after ischemia. (2) C1 inhibitor did not stop the increase in astrocyte activation
(52) Ischemic stroke Rat Permanent MCAO WT + CVFc
WT + CRP
All pathways (1) CVF did not affect the infarct volume. (2) Infarct volume significantly increased after CRP 
treatment
(63) Ischemic stroke Mouse Transient- MCAO 
(120 min occlusion time)
WT + C1 Inhibitor Classical 
pathway
(1) C1 inhibitor given at time of ischemia reduced general and focal deficits and reduced ICAM-1 
and P-selectin expression. (2) C1 inhibitor also reduced pro-caspase-3 and neurofilament H 
expression and affected cytokine levels
(64) Ischemic stroke Mouse Transient- MCAO (30 min 
occlusion time)
WT + C1 Inhibitor Classical 
pathway
(1) C1 inhibitor reduced infarct volume in a dose-dependent fashion only when given before 
reperfusion. (2) C1 inhibitor also reduced general and focal deficits, neuronal apoptosis and 
leukocyte infiltration up to 4 days. (3) C1q−/− had non-significant reduction in infarct volume, but 
significant reduction in ischemic volume
C1q−/−
(65) Ischemic stroke Mouse Transient- MCAO (60 min 
occlusion time)
WT + C5aRAd All pathways C5aRA had significant reduction in infarct volume and improved neurological outcome 24 h after 
ischemia
(66) Ischemic stroke Mouse Transient- MCAO (60 min 
occlusion time) and 
permanent MCAO
WT + C3aRAe All pathways (1) C3aRA caused smaller infarct volume less upregulation of C3aR-positive granulocytes, and 
less ICAM-1 protein on endothelial cells. (2) No significant change in infarct volume with C3aRA 
treatment 24 h after reperfusion
(67) Hemorrhagic 
stroke
Mouse Intracerebral hemorrhage WT + C3aRA
WT + C5aRA
WT + C3aRA and C5aRA
All pathways (1) All three groups had better performance in morris water maze compared to vehicle. (2) C5aRA 
only and double treatment showed significant improvement on corner turn test, better neurological 
score, and reduced granulocytes 72 h after surgery
TABLe 2 | Continued
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(51) Ischemic stroke Rat Transient MCAO (30 min) 
for adults and unilateral 
carotid artery ligation 
followed by hypoxia in 
neonates
WT + CVFc pretreatment All pathways CVF reduced IV in adults and significantly preserved parenchymal volume in neonates and reduced 
cerebral atrophy 2 days after surgery
(42) Ischemic stroke Mouse Transient- MCAO (60 min 
occlusion time) and 
permanent MCAO
WT + IVIG
WT + C5aRA
C5−/−
Non-specific (1) IVIG reduced mortality, infarct size, and functional impairment. (2) C5−/− mice had improved 
outcome and less damage than controls, but C5aR Ant did not improve the outcome significantly. 
(3) IVIG significantly reduced C3b levels compared to controls as well as levels of ICAM-1, CD11a, 
and CD11b at 72 h post reperfusion
(68) Ischemic stroke Baboons Cerebral artery clips 
(75 min)
WT + sCR1-sLex Classical 
pathway
(1) sCR1-Lex significantly lowered CH-50 but had no significant effect on neurological outcome. (2) 
sCR1-Lex-treated baboons had a larger infarct volume compared to controls
(69) Hemorrhagic 
stroke
Mouse Intracerebral hemorrhage WT + C3aRA Non-specific (1) C3aRA pretreatment caused less peri-hematomal edema but no change in hematoma size 
and a gradual recovery of function not significant compared to vehicle. (2) C3aRA treatment post 
reperfusion had no significant reduction in edema or improvement of outcome up to 72 h
(70) Ischemic stroke Mouse Transient- MCAO (30 min 
occlusion time) and 
permanent MCAO
WT + recombinant C1 
Inhibitor (Rh C1Inh)
Classical 
pathway
(1) RhC1Inh but not pdC1Inh bound to MBL and was more effective inhibiting lectin pathway. (2) 
C1Inh reduced infarct volume if given up to 18 h post transient ischemia or within 6 h of permanent 
occlusion
WT + plasma derived C1 
Inhibitor (pdC1Inh)
(71, 
72)
Ischemic stroke Mouse Transient- MCAO (60 min 
occlusion time)
C3−/−
C6−/−
C1q/MBL−/−
Factor B−/−
CD59−/−
WT + CR2-fHf
WT + CR2-Crryg
Classical and 
alternative 
pathway.
(1) Factor B−/−, C1q/MBL−/−, CR2-fH and CR2-Crry but not C6−/− improved neurological outcome 
and reduced infarct volume. (2) CR2-fH was found also to reduce astrocyte reactivity and cellular 
apoptosis. (3) Reduction of infarct volume with CR2-fH was also seen at 7 days post reperfusion. 
(4) CD 59 deficiency did not affect injury after 60 min ischemia
(73) Ischemic stroke Mouse Transient- MCAO (30 min 
occlusion time)
WT + C3aRA All pathways Acute (45 min before ischemia and then daily) C3aRA treatment (1) increased neurogenesis in 
a dose-dependent fashion on day 7, (2) reduced T-cell infiltration, (3) reduced infarct volume, 
mortality and neurological deficit
(74) Ischemic stroke Mouse Transient- MCAO (60 min 
occlusion time)
MBL+/+
MBL−/−
Lectin 
pathway
(1) 15 min post reperfusion, CD11b increased in both neutrophils of MBL+/+ and MBL−/− without 
difference but significantly more than sham. (2) There was no significant difference in infarct 
volume, brain edema, C3 and C1q deposition between MBL+/+ and MBL−/− groups at 24 h after 
reperfusion
(75) Ischemic stroke Mouse Permanent MCAO Adrenomedullin (AM)−/−
Factor H−/−
Alternative 
pathway
(1) Both AM−/− and Factor H−/− did not cause a significant change in infarct volume, endothelial 
NOS, MMP9, and COX-2 at 2 days after ischemia. (2) Bechlin-1 significantly increased after injury 
and together with iNOS was significantly higher in AM−/− compared to WTh
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(76) Ischemic stroke Mouse Transient- MCAO (60 min 
occlusion time)
CD59a−/− All pathways (1) CD59a−/− mice had more neurological impairment 30 min after MCAO and increased neuronal 
apoptosis at 1 h. (2) CD59a deficiency did not affect number of CD11b positive cells
(77) Ischemic stroke Mouse Transient- MCAO 
(120 min occlusion time)
MBL−/−
MBL−/− + MBL
Lectin 
pathway
(1) MBL deficiency resulted in significantly reduced infarct volume, neurological impairment and C3 
deposition. (2) Reconstitution of MBL in MBL−/− mice resulted in a larger infarct volume. Outcomes 
were measured at 48 h
(78) Ischemic stroke Rat Transient- MCAO 
(120 min occlusion time)
WT + sCR1 Classical 
pathway
sCR1 significantly reduced infarct volume, myeloperoxidase activity, and C3d deposition 24 h after 
reperfusion
(79) Ischemic stroke Mouse Neonatal hypoxia C1q−/− Classical 
pathway
(1) C1q−/− mice had significantly lower infarct volume, improved neurological score, lower C3 
deposition, and less leukocyte activation at 24 h. (2) C1q−/− mice also had lower cerebral atrophy 
and better performance on water maze up to 8 weeks after hypoxia-ischemia
(80) Ischemic stroke Rat Photochemical cortical 
vein occlusion
WT + C1 Inhibitor Classical 
pathway
C1 Inhibitor significantly reduced infarct volume 2 h after occlusion
(32) Ischemic stroke Mouse Permanent MCAO C3−/−
WT + C3aRA
All pathways Both C3−/− and C3aRA reduced ischemia-induced neurogenesis in the sub-ventricular zone, infarct 
area, and penumbra at 7 days after injury despite no significant change in infarct volume
(81) Ischemic stroke Rat MCAO None All pathways CD11b, C1q, and C3c increased significantly in ischemic brain and remained elevated till 7 days
(82) Ischemic stroke Mouse Transient- MCAO (90 min 
occlusion time)
MBL−/− Lectin 
pathway
(1) MBL−/− significantly reduced infarct volume and neurological deficit on days 1 and 7 after 
reperfusion. (2) MBL−/− reduces fibrinogen accumulation in brain vasculature 
WT
(83) Ischemic stroke Mouse Transient- MCAO (60 min 
occlusion time)
MBL−/−
WT
Lectin 
pathway
(1) MBL-a/c were found to accumulate in the brain after stroke peaking at 24 h. (2) MBL−/− 
improved acute (day 1) but not subacute (day 7) measures of infarct volume and neurological 
deficit
(84) Ischemic stroke Mouse Permanent and transient-
MCAO (30 min occlusion 
time)
MBL−/−
WT
WT + polymannosylated 
dendrimers
Lectin 
pathway
(1) MBL is deposited on ischemic vessels with a peak at 24 h and is associated with increased C3 
deposition. (2) MBL−/− mice had significantly lower infarct volume compared to WT after permanent 
and transient MCAO. (3) Polymannosylated dendrimers (specifically Polyman2) given up to 30 h 
after reperfusion significantly reduced C3 deposition, infarct volume, and neurological deficit in WT 
mice at 48 h only in transient MCAO
(84) Ischemic stroke Rat Three-vessel occlusion WT Lectin 
pathway
(1) Anti-MBL-A antibody given up to 18 h after ischemia reduced neurological deficit and infarct 
volume at 48 h. (2) The protective effect of anti-MBL-A administration was maintained up to 
28 days after ischemiaWT + anti-MBL-A
aExpress SOD1.
bPBN is an antioxidant.
cCVF, cobra venom factor (deplete complements).
dC5aRA, C5a receptor antagonist.
eC3aRA, C3a receptor antagonist.
fCR2-fH, targeted inhibitor of factor H.
gCR2-Crry, targeted inhibitor of complement activation.
hNOS, nitric oxide synthase; COX-2, cyclo-oxygenase 2; MMP9, matrix metalloproteinase 9; iNOS, inducible nitric oxide synthase.
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complement hemolytic activity, but failed to improve neurological 
outcome; in fact, treatment increased infarct volume in baboons. 
One possible explanation for this outcome is that sCR1-sLex has 
multivalent selectin-targeting sites and may promote homotypic 
platelet–platelet aggregation, and potentially thrombosis.
Another strategy used to target complement inhibition to an 
anatomical site is to link a complement inhibitor to a recombinant 
portion of complement receptor type 2 (CR2). Ligands for CR2 
are C3 activation products that become covalently attached 
at sites of complement activation (57). Complement receptor 
1-related gene/protein-y (Crry) is a rodent structural and func-
tional analog of CR1, and a CR2-Crry construct administered 
90  min after ischemia in a murine MCAO model was shown 
to improve survival, reduce infarct volume, reduce P-selectin 
expression and neutrophil recruitment, and improve neurologi-
cal outcome. Acute outcomes after a single injection of CR2-Crry 
were comparable to those in C3-deficient mice (57). It has also 
been shown that targeted complement inhibition with CR2-Crry 
does not impair host susceptibility to infection, unlike systemic 
inhibition of C3 deficiency, a potentially important consideration 
for stroke patients who are at increased risk of infection (57).
The sCR1 and Crry inhibitors described above are pan comple-
ment inhibitors. Interventional studies in experimental models 
of stroke have also been performed with C1-inhibitor (C1-inh) 
that inhibits only the classical and lectin pathways. In various 
ischemic stroke models, C1-inh has been shown to decrease 
infarct volume (56, 62, 64, 70, 80), reduce focal and general defi-
cits (62–64), inhibit leukocyte infiltration and myeloperoxidase 
activity (56, 63, 64), and diminish neuronal apoptosis (63, 64) 
(summarized in Table 2). Taken together with the data reported 
above that C1q deficiency is not protective in murine models of 
ischemic stroke, these data suggest a role for the lectin pathway 
in promoting cerebral IRI. Of note, however, all of the studies 
with C1-inh evaluated acute outcome after stroke, and it is pos-
sible that C1q-mediated uptake of apoptotic cells, an important 
anti-inflammatory and reparatory mechanism, may play a role in 
outcome in the subacute phase after stroke.
Further investigation has indeed demonstrated an important 
role for the lectin pathway in murine models of stroke. MBL defi-
ciency resulted in significantly reduced infarct volumes, neuro-
logical impairment, and C3 deposition, whereas reconstitution of 
MBL-deficient mice with MBL resulted in larger infarct volumes 
(77). Two additional studies have also since demonstrated that 
MBL deficiency is protective against ischemic stroke (82, 84), and 
it has also been shown that an inhibitor of the lectin pathway, 
Polyman2, is protective when given up to 24  h after ischemia 
in mice (84). The same study demonstrated that an anti-MBL 
antibody is also protective in a rat model of stroke when given 
up to 18 h after ischemia, and as assessed 28 days after stroke. 
Thus, lectin pathway inhibition appears to be a therapeutic target 
with a wide therapeutic window. It should be noted, nevertheless, 
that Morrison et al. [(74) p. 52] found no significant difference 
in infarct volume, brain edema, or complement deposition 
between wild-type and MBL-deficient mice, and that Ducruet 
et  al. (83) found that acute-phase protection in MBL-deficient 
mice was not sustained in the subacute phase. With regard to the 
different subacute outcomes in lectin pathway deficient vs. lectin 
pathway inhibited mice, an explanation could be that while acute 
complement activation is injurious, it also plays a role in repair 
and regenerative mechanisms in the subacute phase. Unlike 
deficiency, acute temporary lectin pathway inhibition would have 
minimal impact on the lectin pathway in the subacute phase.
The alternative complement pathway can be spontaneously 
activated, but it also serves as an amplification loop for the classi-
cal or lectin pathways. Whichever way complement is activated, it 
has been estimated that 80% of complement activation products 
can be the result of alternative pathway amplification (92). This is 
likely the reason that although the classical and lectin pathways 
can variously play essential roles in autoimmune, inflammatory, 
and ischemic disease models, the alternative pathway is nearly 
always required for full in vivo expression of injury (93, 94). And 
cerebral IRI is no exception, since although the studies reported 
above indicate a key role for the lectin pathway in ischemic 
stroke, mice deficient in factor B (alternative pathway protein) 
or treated with CR2-fH (targeted alternative pathway inhibitor) 
were protected to a similar extent as C1q/MBL-deficient mice 
in terms of several injury and neurological outcome measures 
(72). Together these data indicate that the alternative pathway is 
not alone sufficient to initiate complement activation, but that it 
acts to propagate cerebral injury via amplification of the cascade. 
Of note, a single CR2-fH treatment administered 90  min post 
ischemia resulted in significantly reduced astrocyte reactivity, 
cellular apoptosis and infarct volume for up to 7 days after rep-
erfusion (72). In unpublished work, we have shown that unlike 
CR2-fH, CR2-Crry does not provide sustained protection into 
the subacute phase after stroke. This may reflect an advantage 
of not blocking all complement pathways in order to maintain 
some level of complement activation that may contribute to 
homeostatic or repair processes.
With regard to the terminal complement pathway, data indicate 
that the MAC is an important mediator of IRI in several organs 
and tissues, including spinal cord injury (95) and traumatic brain 
injury (96). In the case of cerebral IRI, however, the role of the 
MAC is less clear. Mice deficient in C6, a component of the MAC, 
are not protected from cerebral injury after 60 min MCAO and 
24 h reperfusion, indicating that the MAC does not play a role 
in cerebral IRI (72). In agreement with this conclusion, mice 
deficient in CD59, a membrane-bound inhibitor of the MAC, 
do not display exacerbated cerebral injury in the same model 
(72). However, CD59-deficient mice show worse outcomes in the 
MCAO model with shorter ischemic times (30 min as opposed 
to 60 min), and thus the terminal pathway may contribute to cer-
ebral IRI under conditions of less severe injury or ischemia (76).
Studies on the anaphylatoxins, C3a and C5a, have indicated 
important roles for these peptides in cerebral IRI. In a transient 
MCAO model, C3-deficient mice and wild-type mice treated 
with a C3a receptor antagonist (C3aRA) showed significant 
improvements in infarct volume and neurological outcomes, with 
less granulocyte infiltration. Furthermore, the effect was reversed 
when C3-deficient mice were reconstituted with C3 (60). A simi-
lar effect of C3aRA was shown in a transient MCAO model (66), 
but not in a model with permanent occlusion (73). The different 
effects of C3aRA in the two models may be related to inhibition 
of C3a-dependent activation of blood-derived immune cells 
FiGURe 3 | Triggers of complement activation after cerebral ischemia-
reperfusion injury. Ischemic insult induces expression of neoepitopes or 
danger-associated molecular patterns (DAMPs) on the surface of stressed 
endothelial cells. The exposed DAMPs are recognized by circulating natural 
self-reactive antibodies, principally IgM, which triggers complement activation. 
Although IgM binds C1q, it appears to be the binding of MBL and activation of 
the lectin pathway that drives ischemia and reperfusion injury in the organs 
systems examined, including the brain. Complement can be also activated 
through direct binding of C1q to apoptotic cells, as well as through C-reactive 
protein-induced complement activation.
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following reperfusion. C5aR1-deficient mice are also protected 
against cerebral IRI following transient MCAO (44), but pretreat-
ment of wild-type mice with C5aRA did not consistently improve 
neurological outcome or infarct volume (42, 65). Interestingly, 
C5aRA was also found to improve outcome in animal models of 
hemorrhagic stroke, either alone or in combination with C3aRA 
(53, 67, 69). These studies on the role of C3a and C5a in stroke 
pathogenesis were performed by analyzing acute outcomes, 
and it remains unclear what effect interfering with C3a- and 
C5a-mediated signaling would have on subacute and chronic 
outcomes. A concern with inhibiting C3a and C5a signaling, 
especially at later time points after stroke, is the effect on neu-
rogenesis and cognitive performance, since both anaphylatoxins 
have implicated roles in basal and stress-induced neurogenesis 
(32–34). In this regard, a study using C3aRA treatment after 
MCAO indicated that the effect of C3a inhibition on neurogen-
esis is dose dependent. High-dose treatment with C3aRA (twice 
daily for 10 days) reduced ischemia-induced neurogenesis in the 
sub-ventricular zone, infarct area, and penumbra at 7 days after 
permanent MCAO (32). However, low dose C3aRA treatment 
increased neurogenesis in a dose-dependent fashion on day 7 in 
a transient MCAO model with 30 min ischemia (73). This may 
indicate that a titrated reduction of C3a-dependent signaling may 
limit the pro-inflammatory effects of C3a (especially in models 
that include reperfusion), while at the same time maintain the 
homeostatic effects of C3a on neurogenesis.
So what is the complement-activating event after stroke? 
Seminal studies by Williams et al. (97) and Zhang et al. (98, 99) 
demonstrated that following intestinal ischemia and reperfusion, 
complement is activated by natural self-reactive IgM antibodies 
that recognize post-ischemic neoepitopes. By screening IgM-
producing hybridomas, an IgM monoclonal antibody was iso-
lated that could restore pathogenic injury in otherwise protected 
antibody-deficient (Rag1−/−) mice. The intestinal target of this 
mAb was identified as non-muscle myosin (98), and antibodies 
to this post-ischemic neoepitope have additionally been shown to 
play a role in hind-limb (100) and myocardial IRI (101). Although 
the early studies attributed IgM-mediated activation of the clas-
sical pathway as an initiating event in IRI, more recent studies 
have demonstrated that IRI is driven by IgM-mediated activation 
of the lectin pathway, at least in the organ systems that have 
been investigated (99, 102, 103). The animal studies described 
above, and the human studies described below, indicate that the 
lectin pathway also initiates cerebral IRI, and recent studies have 
demonstrated that pathogenic natural IgM also plays a role in 
propagating injury in murine ischemic stroke (71) (Figure  3). 
As with intestinal IRI, Rag1-deficient mice are protected from 
cerebral IRI, and two IgM monoclonal antibodies were identi-
fied that reconstituted cerebral IRI in Rag1-deficient mice; these 
monoclonal antibodies recognized annexin IV and a subset of 
phospholipids, and thus identified danger-associated molecular 
determinants expressed after stroke in mice (71). Post-ischemic 
blockade of annexin IV or phospholipid neoepitopes thus repre-
sents a potential therapeutic strategy for inhibiting complement 
activation and reducing cerebral IRI. The same two post-ischemic 
neoepitopes are also expressed in the intestine (104) and heart 
[(57), Circulation, in press] after ischemia and reperfusion, 
indicating that similar pathophysiologically important epitopes 
recognized by IgM natural antibodies are expressed in different 
organs and tissues. Furthermore, it has been shown that human 
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endothelial cells (HUVEC) express these two neoepitopes after 
exposure to hypoxia (71).
Studies in Human Patients
There are no reported clinical trials on the use of complement 
inhibition in stroke, a direct consequence of the aforementioned 
conflicting pre-clinical data. Before an intervention can enter 
a clinical trial, stringent criteria recommended by the stroke 
therapy academic industry roundtable (STAIR) must be met. 
In brief, there should be consistent pre-clinical data in different 
animal species and in animal cohorts that represent the human 
stroke predisposed population. Such populations include both 
sexes, adult and elderly age groups, and patients with comorbidi-
ties such as hypertension and diabetes (105). Thus, studies on the 
role of complement in human stroke are correlational.
Studies on gene polymorphisms at complement gene loci, 
associated polymorphisms at the C5 and factor H gene loci with 
increased incidence of cerebrovascular accidents (106, 107). 
Among 16 single nucleotide polymorphisms (SNPs) at the C3 
gene locus, two SNPs (rs2277984 and rs3745565) were associated 
with ischemic stroke (108). MBL genotype is also associated with 
stroke severity. In two cohorts of stroke patients, MBL-sufficient 
phenotypes were associated with larger infarct and less favorable 
outcome compared to MBL-deficient phenotypes (77, 109). 
Prospective studies on men with advanced atherosclerosis, higher 
levels of C4 and C5 are associated with the incidence of stroke 
(110). Similarly, a prospective study of 5850 healthy men showed 
that C4 and C3 levels correlated with other cardiovascular risk 
factors, and that very high C4 levels may predict the incidence 
of stroke (111). C4 was also shown to be a stroke predictor in 
men with known or suspected coronary artery disease (112). 
Compared to healthy volunteers, stroke patients were found to 
have higher plasma levels of C3a, C3, C4, C5, factor B, and the 
terminal complement complex (113–118). Serum levels of C3, 
C3c, and C4 were also associated with increased stroke severity in 
cardio-embolic stroke patients (118, 119). Despite these human 
studies that report alterations in serum complement levels in 
stroke patients and the association with outcome, the studies 
remain correlative and cannot demonstrate a definitive role for 
complement in the pathogenesis of stroke. Table 3 summarizes 
studies investigating complement system changes in patients with 
ischemic or hemorrhagic stroke.
Future Perspectives on the Dual role of 
Complements in Brain i/R
The predominant focus of studies on complement and stroke has 
been on the role of complement in perpetuating the inflammatory 
cascade and contributing to neuronal death. By comparison, very 
few studies have investigated the putative protective role that 
complement may play in ischemic rescue and ischemia-induced 
neurogenesis. The great majority of reports investigate acute-
phase outcomes where complement blockade prevents activation 
of pro-inflammatory mechanisms. However, as indicated by a few 
studies, the same favorable outcomes may not occur in the suba-
cute and chronic phases after stroke, when complement opsonins 
may be important for mediating anti-inflammatory events such 
as removal of debris, and when anaphylatoxins may contribute 
to homeostatic pro-survival and neuro-regenerative effects. It 
will be important to investigate how manipulation of the comple-
ment system impacts subacute and chronic outcomes, as well as 
to evaluate areas away from the ischemic core. Investigation of 
chronic outcomes may reveal a role for complement in maintain-
ing neuronal survival after acute damage has been resolved, and 
possible mechanisms may include stimulation of neuronal growth 
factor production by astrocytes and microglia (35, 36), or reduc-
tion of glutamate-induced excitotoxicity (37–40). Stroke and brain 
injury are associated with a window of synaptic plasticity after 
injury that contributes to neurological recovery (88, 90). While 
various mechanisms have been implicated in this process, a role 
for complement has not been investigated. Based on the essential 
role of complement in synaptic pruning during CNS develop-
ment, complement may also play a role in synaptic pruning and 
hippocampal plasticity after stroke, and may thus contribute to 
improved neurological outcome and facilitate rehabilitation.
Going forward, the design of experimental models to assess 
longer endpoints and multiple outcome measures after stroke 
may reveal a more diverse role for complement in ischemic injury 
and rescue. Future studies should also investigate the role of dif-
ferent complement components in early and delayed pathophysi-
ological events. One area of investigation that has received little 
attention is the role of complement opsonins in early neuronal 
and synaptic loss after stroke, as well as the role of these opsonins 
in the resolution of inflammation and synaptic re-wiring that 
can occur later. Future studies should also address the interplay 
between complement opsonins and immune cells bearing 
receptors for these opsonins, especially infiltrating and resident 
macrophages/microglia; these opsonins may also play a role in 
driving macrophage polarization toward an anti-inflammatory 
and pro-regenerative phenotype. We also have an incomplete 
understanding of the role of the anaphylatoxins in stroke. They 
are implicated in recruiting and activating immune cells acutely, 
as well as stimulating neuronal genesis and migration in delayed 
phases after stroke. It is also not clear whether C3a and C5a have 
redundant, overlapping, or possibly divergent effects. Tools to 
address these questions are available in the form of genetically 
deficient mice and inhibitors that block the generation of specific 
complement activation products or that antagonize complement 
receptors, and it will be important for future studies to better 
evaluate long-term effects and outcomes after stroke.
Clinical and Translational Perspective
As mentioned in Section “Studies in Human Patients,” polymor-
phism in complement genes is associated with ischemic stroke, 
and that acute stroke patients have higher serum levels of com-
plement proteins compared to controls (Table  3). In addition, 
postmortem studies have identified both complement and IgM 
deposition in the human brain after stroke (125). This suggests 
that complement activation and deposition occurs in the human 
brain similarly to that in experimental models. Thus, given the 
correlation between complement activity and stroke outcome in 
human patients, the use of complement inhibition holds promise 
as a potential therapeutic intervention. Optimally, a complement 
TABLe 3 | Summary of studies performed in human patients investigating the role of complement in cerebral i/R.
Study Patient condition Controls Assay Pathway Relevant findings
(118) Cardio-embolic and small 
vessel disease stroke 
(n = 79 each)
Matched control 
groups (n = 40 each)
ELISA for C3 and C3a levels All pathways (1) C3 and C3a were elevated acutely in both 
groups, and only C3 remained elevated at 
3 months in both groups.(2) Phasic increase of 
C3 was associated with unfavorable outcome 
only in cardio-embolic patients
(120) Coronary vessel disease, 
MI, and ischemic stroke (n 
~55 each)
Matched controls Immunofluorometric assay of 
MASP-1,2,3,4
Lectin pathway (1) MASP-1 and MASP-2 levels were low in 
stroke patients. (2) MASP-3,4 levels were not 
different from controls
(107) Carotid atherosclerosis 
(n = 1065)
None Polymorphism in C5 gene All pathways Polymorphism of C5 gene was associated with 
increased plasma C5a levels and increased 
incidence of MACE in men
(121) Fatal ischemic brain 
infarction (n = 10)
None Immunohistochemistry of C9 
deposition
Common 
terminal 
pathway
Infarct areas associated with increased C9 
deposition and neutrophil infiltration
(113) Acute stroke (n = 11) Healthy volunteers 
(n = 9)
Serum levels of complement and 
inflammatory components
Common 
terminal 
pathway
(1) Terminal complement complex and CRP 
levels increased at 3–12 days after stroke 
compared to controls. (2) No significant 
change in soluble adhesion molecules and 
cytokines
(122) Cerebrovascular disease 
(n = 292)
Healthy volunteers 
(n = 198)
Genotype of C4B alleles. Classical 
pathway
There was significantly lower incidence of allo-
type C4B1Q0 in patients with cerebrovascular 
disease compared to control
(119) Cardio-embolic, 
thromboembolic, and 
lacunar stroke patients 
(n = 194)
NA C3c and C4 Classical and 
alternative 
pathways
(1) Serum concentration of C3c and C4 was 
significantly reduced in cardio-embolic stroke 
compared to atherothrombotic and lacunar 
strokes. (2) Serum concentration reflects the 
stroke severity only in cardio-embolic stroke
(110) Advanced atherosclerosis 
(n = 173)
None C5a All pathways Complement activation with increased C5a 
levels is associated with higher risk of MACE.
(123) Ischemic stroke (n = 80) None Platelet C4d levels Classical 
pathway
Platelet C4d is associated with severe acute 
ischemic stroke.
(124) Ischemic stroke (n = 26) Severe carotid 
atherosclerosis 
(n = 26)
sC5b-9 and C4d levels Classical and 
common 
terminal 
pathway
(1) sC5b-9 and C4d were higher in stroke 
patients. (2) Levels of sC5b-9 were associated 
with stroke severity and functional disability
(125) Brains of stroke patients 
(n = 10)
Control brains (n = 10) Postmortem complement levels. Classical and 
common 
terminal 
pathway
Ischemic areas showed C1q, C4d, and C3c 
deposition as well as marked reduction in 
CD59 compared to normal tissue
(108) Stroke patients (n = 844) Healthy controls 
(n = 668)
Assay of 16 SNPs at C3 locus. All pathways Two SNPs at the C3 gene locus (rs2277984 
and rs3745565) were associated with ischemic 
stroke
(116) Stroke patients (n = 179) Healthy controls 
(n = 156)
C3 and C4 plasma levels and 
complement hemolytic activity.
All pathways Complement levels of C3 and C4 were 
elevated in stroke patients and associated with 
a worse neurological outcome.
(59, 60, 
115)
Stroke patients (n = 16) Healthy controls 
(n = 16)
C3a, C5a, and sC5b-9 levels in 
plasma
All pathways (1) C3a was significantly elevated in stroke 
patients compared to controls till day 28. (2) 
C5a levels were elevated at 7–14 days. (3) 
sC5b-9 levels were significantly depressed in 
stroke patients till day 2.
(112) Men with known or 
suspected coronary artery 
disease (n = 389)
None C4 plasma levels Classical 
pathway
Serum component C4 is predictor of stroke 
with known or suspected heart disease.
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inhibitor should effectively inhibit early pathogenic complement 
activation without depleting systemic complement activity in 
order to maintain the homeostatic and protective role of com-
plement during recovery. A clear understanding of the role of 
different complement activation products and their spatial and 
temporal effects will be important to guide the development of 
an optimal anti-complement therapeutic strategy. As a final note, 
thrombolytic therapy using t-PA also results in complement 
activation (130), and it is possible that complement inhibition in 
the context of t-PA administration could provide a new adjuvant 
therapy to t-PA.
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Study Patient condition Controls Assay Pathway Relevant findings
(111) Initially healthy men 
(n = 5850)
None C3 and C4 plasma levels. Classical and 
common 
terminal 
pathway
(1) Serum C3 and C4 levels correlated with 
other cardiovascular risk factors. (2) Very 
high C4 levels may be associated with stroke 
incidence
(126) First degree relatives to 
South Asian stroke patients 
(n = 143)
South Asian (n = 121) 
and white (n = 141) 
controls
C3, factor B, and CRP plasma 
levels
Alternative 
pathway
(1) No significant difference in C3, CRP, and 
factor B levels between South Asian first 
degree relatives and controls. (2) Only C3 and 
CRP levels were higher in South Asian groups 
compared to controls
(106) Caucasians who developed 
a ischemic stroke (n = 235)
Controls (n = 235) Complement factor H Y402H 
gene polymorphism
Alternative 
pathway
No association of Y402H polymorphism with 
risk of ischemic stroke
(117) Cryptogenic stroke (n = 79) 
and large vessel disease 
stroke (n = 73)
Controls (n = 79) Plasma C3 and C3a levels All pathways (1) C3 levels were elevated in stroke patients 
compared to controls. (2) Higher C3a levels 
were associated with stroke. (3) Plasma 
levels of C3 were associated with unfavorable 
outcome in large vessel disease patients at 
3-month and 2-year interval.
(109) Ischemic stroke (n = 353) None MBL plasma levels. Lectin pathway MBL deficiency is associated with smaller 
cerebral infarcts and favorable outcome in 
patients receiving conservative treatment. 
(77) Ischemic Stroke (n = 135) 
and hemorrhagic stroke 
(n = 26)
None MBL genotype and plasma 
levels.
Lectin pathway Unfavorable outcome was associated with 
MBL-sufficient genotype and MBL-circulating 
level
(127) Patients with first ischemic 
stroke (n = 1451)
None C3 and C4 plasma levels. Terminal 
Pathway
C3 (not C4) levels of stroke patients on 
admission was independently associated with 
prognosis in male patients 3 months after the 
acute event
(128) Patients with first ischemic 
stroke (n = 220)
Healthy controls 
(n = 100)
MBL plasma levels. Lectin Pathway MBL was an independent prognostic marker 
of functional outcome and death 90 days after 
stroke
(129) Infants with hypoxic-
ischemic encephalitis 
(n = 16)
Healthy controls (n = 7) C9 and MAC levels in CSF. Terminal 
pathway
(1) Infants with hypoxic-ischemic encephalitis 
had significantly higher MAC levels and 
significantly lower C9 levels in CSF compared 
to controls. (2) Postmortem staining of brain 
tissue of two infants revealed C9 deposition on 
morphologically apoptotic neurons.
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